{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-022396","form_type":"8-K","ticker":"ABVC","cik":"0001173313","company_name":"ABVC BIOPHARMA, INC.","filed_at":"2024-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.558766+00:00","generated_at":"2026-06-04T18:49:48.909900+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ABVC BioPharma FY2023 revenue falls 84% to $152K; net loss narrows to $10.9M","bullets":["Revenue of $152,430 in FY2023, down from $969,783 in FY2022; net loss improved 31% to $10.9M.","Operating expenses cut to $8.07M from $15.8M; cash and cash equivalents only $60K as of Dec 31, 2023.","Entered global licensing agreement with AIBL for CNS drugs; received 23M AIBL shares valued at $10 per share.","Regained Nasdaq compliance for $1.00 bid price and $2.5M stockholders' equity requirements in Aug/Sep 2023.","Stockholders' equity of $8.39M at year-end; raised $1.75M via registered direct offering in July 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-022396","json":"https://secwatch.observer/filing/0001213900-24-022396.json","markdown":"https://secwatch.observer/filing/0001213900-24-022396.md","text":"https://secwatch.observer/filing/0001213900-24-022396.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173313/000121390024022396/0001213900-24-022396-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173313/000121390024022396/ea0201766-8k_abvcbio.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T18:49:48.909900+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f77569f2f1e0e8ed46f00a5523237c839f1a9b51","claim":"ABVC BIOPHARMA, INC. reported financial results for the fiscal year ended December 31, 2023.","evidence_excerpt":"ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes, announced its 2023 annual financial and operating results.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1173313/000121390024022396/0001213900-24-022396-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}